Semaglutide ingredient can help protect kidney function in people with obesity
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown in the SELECT Trial to be effective in preventing the loss of kidney function in people who are overweight or obese and have established cardiovascular disease but do not have diabetes. Read further on Dynamite News: